215 related articles for article (PubMed ID: 28981753)
1. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
[TBL] [Abstract][Full Text] [Related]
2. Creating stable stem regions for loop elongation in Fcabs - insights from combining yeast surface display, in silico loop reconstruction and molecular dynamics simulations.
Hasenhindl C; Lai B; Delgado J; Traxlmayr MW; Stadlmayr G; Rüker F; Serrano L; Oostenbrink C; Obinger C
Biochim Biophys Acta; 2014 Sep; 1844(9):1530-40. PubMed ID: 24792385
[TBL] [Abstract][Full Text] [Related]
3. Two-faced Fcab prevents polymerization with VEGF and reveals thermodynamics and the 2.15 Å crystal structure of the complex.
Lobner E; Humm AS; Mlynek G; Kubinger K; Kitzmüller M; Traxlmayr MW; Djinović-Carugo K; Obinger C
MAbs; 2017 Oct; 9(7):1088-1104. PubMed ID: 28816592
[TBL] [Abstract][Full Text] [Related]
4. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.
Traxlmayr MW; Lobner E; Antes B; Kainer M; Wiederkum S; Hasenhindl C; Stadlmayr G; Rüker F; Woisetschläger M; Moulder K; Obinger C
Protein Eng Des Sel; 2013 Apr; 26(4):255-65. PubMed ID: 23267121
[TBL] [Abstract][Full Text] [Related]
5. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.
Wozniak-Knopp G; Bartl S; Bauer A; Mostageer M; Woisetschläger M; Antes B; Ettl K; Kainer M; Weberhofer G; Wiederkum S; Himmler G; Mudde GC; Rüker F
Protein Eng Des Sel; 2010 Apr; 23(4):289-97. PubMed ID: 20150180
[TBL] [Abstract][Full Text] [Related]
6. Yeast Surface Display and Cell Sorting of Antigen-Binding Fc Fragments.
Sádio F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Methods Mol Biol; 2019; 1923():287-308. PubMed ID: 30737746
[TBL] [Abstract][Full Text] [Related]
7. Engineered IgG1-Fc--one fragment to bind them all.
Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
[TBL] [Abstract][Full Text] [Related]
8. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening.
Choi HJ; Kim YJ; Choi DK; Kim YS
PLoS One; 2015; 10(12):e0145349. PubMed ID: 26675656
[TBL] [Abstract][Full Text] [Related]
9. Fcab-HER2 Interaction: a Ménage à Trois. Lessons from X-Ray and Solution Studies.
Lobner E; Humm AS; Göritzer K; Mlynek G; Puchinger MG; Hasenhindl C; Rüker F; Traxlmayr MW; Djinović-Carugo K; Obinger C
Structure; 2017 Jun; 25(6):878-889.e5. PubMed ID: 28528777
[TBL] [Abstract][Full Text] [Related]
10. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M
Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.
Woisetschläger M; Antes B; Borrowdale R; Wiederkum S; Kainer M; Steinkellner H; Wozniak-Knopp G; Moulder K; Rüker F; Mudde GC
Biotechnol J; 2014 Jun; 9(6):844-51. PubMed ID: 24806546
[TBL] [Abstract][Full Text] [Related]
12. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution.
Traxlmayr MW; Lobner E; Hasenhindl C; Stadlmayr G; Oostenbrink C; Rüker F; Obinger C
Biotechnol J; 2014 Aug; 9(8):1013-22. PubMed ID: 24964247
[TBL] [Abstract][Full Text] [Related]
13. Selection of High-Affinity Heterodimeric Antigen-Binding Fc Fragments from a Large Yeast Display Library.
Benedetti F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Methods Mol Biol; 2023; 2681():131-159. PubMed ID: 37405647
[TBL] [Abstract][Full Text] [Related]
14. Applications for an engineered Protein-G variant with a pH controllable affinity to antibody fragments.
Bailey LJ; Sheehy KM; Hoey RJ; Schaefer ZP; Ura M; Kossiakoff AA
J Immunol Methods; 2014 Dec; 415():24-30. PubMed ID: 25450256
[TBL] [Abstract][Full Text] [Related]
15. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
16. Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding.
Zwolak A; Leettola CN; Tam SH; Goulet DR; Derebe MG; Pardinas JR; Zheng S; Decker R; Emmell E; Chiu ML
Sci Rep; 2017 Nov; 7(1):15521. PubMed ID: 29138497
[TBL] [Abstract][Full Text] [Related]
17. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
[TBL] [Abstract][Full Text] [Related]
18. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.
Liu L; Yu H; Huang X; Tan H; Li S; Luo Y; Zhang L; Jiang S; Jia H; Xiong Y; Zhang R; Huang Y; Chu CC; Tian W
BMC Cancer; 2015 Mar; 15():170. PubMed ID: 25881012
[TBL] [Abstract][Full Text] [Related]
19. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
20. Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds.
Wozniak-Knopp G; Stadlmann J; Rüker F
PLoS One; 2012; 7(1):e30083. PubMed ID: 22272277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
